Clinical trials: Breast Cancer, Metastatic Breast Cancer
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Breast Cancer
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Previous studies have shown that the FGF signaling pathway is closely related to endocrine therapy resistance in breast cancer, but there is not sufficient evidence for the combination of endocrine therapy and FGFR inhibitors.
- Trial name
- NCT04936295
- Testing
- Fulvestrant plus Anlotinib
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia
Planned study population consists of approximately 1,000 adult patients with HER2-positive mBC receiving anti-HER2 therapy in about 50 oncological centers (in each center it is expected to recruit about 20 patients) in different…
- Trial name
- NCT05905939
- Where
- 29 sites in Russia
- Volunteers
- 774 people
- Sponsor
- AstraZeneca
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer.
- Trial name
- NCT06008275
- Testing
- Neratinib Oral Tablet, Ruxolitinib Oral Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
- Trial name
- NCT06064812
- Testing
- FWD1802
- Where
- 22 sites in China
- Volunteers
- 99 people
- Sponsor
- Forward Pharmaceuticals Co., Ltd.
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC.
- Conditions
- Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
- Trial name
- Palbociclib (NCT06338644)
- Testing
- Palbociclib
- Volunteers
- 100 people
- Sponsor
- Helwan University
Breast Cancer
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer.
- Trial name
- NCT05748834
- Testing
- Tucatinib, Doxil
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03803761
- Testing
- Copanlisib, Fulvestrant
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics.
- Trial name
- CATCH (NCT05652569)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- German Cancer Research Center
Breast Cancer
Denosumab for Breast Cancer With Bone Mets
The goal of this clinical research study is to learn if denosumab in combination with a hormonal drug can help lower the number of circulating tumor cells (CTCs) in patients with breast cancer that has spread to the bone.
- Trial name
- NCT01952054
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Soft Tissue Sarcoma
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer
The purpose of this study is to determine whether treatment with temozolomide can effect the survival of patients with advanced breast cancer or soft tissue sarcoma.
- Trial name
- NCT00194766
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Breast Cancer With Brain Metastasis
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
Primary Objective: To determine if treatment with SRS followed by a HER-2 directed therapy regimen results in a 6-month distant brain relapse rate of less than 30%. Secondary Objectives: 1.
- Trial name
- NCT01924351
- Testing
- Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
This study is a retrospective, multi-site, patient-level medical chart review of US adult patients with locally advanced or metastatic breast cancer (ABC) who initiated talazoparib on or after October 16, 2018 and were managed by…
- Trial name
- NCT04987931
- Testing
- Talazoparib
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Breast Cancer
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab.
- Trial name
- Cu-64 HER2+ (NCT00605397)
- Testing
- PET Imaging With Cu-64 Labeled Trastuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasm Female, Neoplasm Metastasis
Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases
The research to be carried out is aimed at patients with metastatic breast cancer, specifically bone metastases. These patients will be recruited from two hospitals in Granada, provided they meet the established inclusion…
- Conditions
- Breast Neoplasm Female, Neoplasm Metastasis, Spinal Neoplasms
- Trial name
- NCT05244382
- Testing
- Overcome
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Universidad de Granada
Metastatic Breast Cancer
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
- Trial name
- NCT00601159
- Testing
- gemcitabine and cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia
Biomarkers in Patients With Metastatic Breast Cancer
In order to allow Tunisian patients with breast cancer to access immunotherapies, and innovative treatments to extend life expectancy of patients with breast cancer with a poor prognosis, it is important to study the…
- Trial name
- BIOPEACE (NCT05871788)
- Testing
- identify biomarkers
- Volunteers
- 1,600 people
- Sponsor
- Tunisian Association for Immuno-oncology Research
Breast Cancer
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05080842
- Testing
- AC682
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Accutar Biotechnology Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.